Abstract

Biomarkers can be objectively measured and evaluate the processes of normal biological pathogenic, and pharmacological answers to medications. This study aimed to evaluate the Cancer antigen 15-3 (CA 15-3); Cancer antigen 19-9 (CA 19-9); Cancer antigen 72-4 (CA 72-4); Cancer antigen 125 (CA 125); Carcinoembryonic antigen (CEA); Neuron-specific enolase (NSE), and their test requests in Ankara Bilkent City Hospital. All the results recorded between 01/01/2022 and 31/12/2022 were acquired from our hospital laboratory information system.136,043 tests, consisting of 28,132 CA 15-3, 37,543 CA 19-9, 3135 CA 72-4, 29,996 CA125, 36,788 CEA, and 449 NSE tests, were enrolled. The frequency of positive tumor markers were as follows: CA 15-3 U/mL (N=996, 3.5%), CA 19-9 U/mL (N=4716,12.6%), CA 72-4 U/mL (N=174, 5.6 %), CA125 U/mL (N=3488, 11.6%), CEA ng/mL (N=1699, 4.6%), NSE IU/ mL (N=396, 88.2%). Statistical differences in CA 15-3 U/mL(p

Key words: Cancer antigen 15-3, cancer antigen 19-9, cancer antigen 72-4, cancer antigen 125, carcinoembryonic antigen, neuron-specific enolase